FDA clears first gene therapy for hemophilia: CSL Behring’s $3.5 million Hemgenix

U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder. The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common form…








